Compare ULCC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | RLAY |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2020 |
| Metric | ULCC | RLAY |
|---|---|---|
| Price | $4.92 | $7.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $5.67 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 02-06-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,729,000,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $19.96 |
| Revenue Next Year | $16.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $2.89 | $1.78 |
| 52 Week High | $10.26 | $9.04 |
| Indicator | ULCC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 47.92 |
| Support Level | $5.06 | $7.36 |
| Resistance Level | $5.52 | $8.64 |
| Average True Range (ATR) | 0.31 | 0.53 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 27.71 | 41.54 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).